The University of Texas System

Sysmex Corporation

Naoto T Ueno

Mien-Chie Hung

Hideki Ishihara

Tomoko Matsushima

Tamotsu Sudo

The present invention provides a method for determining the chemosensitivity of a cancer cell to a taxane comprising assessing the effect of the taxane on the expression level or activity of one or more cell cycle molecules in a cancer cell. Such a method makes use of an automated analyzer system wherein cell cycle parameters (molecules) such as CDK1 kinase activity, CDK1 expression, CDK2 kinase activity, CDK2 expression, MAD2 expression, Cyclin B1, Cyclin E expression, p21 expression, and CDK6 expression; are assessed. The present invention further provides a method of obtaining a cell cycle profile of a cancer cell that is sensitive to a taxane.

Taxane chemosensitivity prediction test

The present invention relates to methods for the inhibition, of the gene product of the neu oncogene, p185neu tyrosine kinase. Over-expression of the neu oncogene leads to chemoresistance. The methods disclosed involve the novel use of E1A and/or LT in combination with chemotherapeutic drugs to treat carcinoma. Furthermore, E1A surprisingly potentiates the antineoplastic effects of the chemotherapeutic agents. The inventors propose that E1A sensitizes cancer cells such that they become amenable to treatment by chemotherapeutic drugs.

Nucleic acid encoding an E1A gene product sensitizes HER-2/neu overexpressing cancer cells to chemotherapy

Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy

Growing community of inventors

Houston, TX, United States of America

Naoto T Ueno